

Proposed Additions and Deletions to the NIOSH Hazardous Drug List 2014						
Established Name	Proprietary Name	Drug Class	Formulation(s)	Dosage	FDA pregnancy Category	Drug Package Insert
Drugs Recommended by NIOSH to be Added to the 2012 Hazardous Drug List						
abacavir	Ziagen	antiviral	tablets, oral solution	600mg	C	PI
abiraterone acetate	Zytiga	antineoplastic; CYP17 inhibitor	tablets	1000mg	X	PI
apomorphine	Apokyn	dopamine agonist	SQ	2-6mg	C	PI
bevacizumab	Avastin	monoclonal antineoplastic	IV	5-15mg/kg	C	PI
crizotinib	Xalkori	antineoplastic	capsules	250mg	D	PI
deferiprone	Ferriprox	FE chelator	tablets	25-30mg/kg	D	PI
dexmedetomidine	Precedex	alpha andrenergic antagonist	IV	0.2-1mcg/kg	C	PI
eribulin mesylate	Halaven	antineoplastic; microtubule inhibitor	IV	1.4mg/m2	D	PI
erlotinib	Tarceva	antineoplastic	tablets	150mg	D	PI
ezogabine	Potiga	anticonvulsant	tablets	100-150mg	C	PI
fingolimod	Gilenya	biological response modulator; sphingosine-1 phosphate recept. modulator	capsules	0.5mg	C	PI
fluconazole	Diflucan	antifungal	tablets, IV, oral suspension	100-400mg	C/D	PI
icatibant	Firazyr	bradykinin B2 receptor antagonist	SQ	30mg	C	PI

liraglutide recombinant	Victoza	antidiabetic agent	SQ	0.6-1.8mg	C	PI
misoprostol	Cytotec	prostaglandin analog	tablets, oral solution	100-200mcg	X	PI
nevirapine	Viramune	antiviral	tablets, oral solution	200mg	B	PI
propylthiouracil		antithyroid	tablets	100mg	D	PI
spironolactone	Aldactone	diuretic	tablets	25-200mg	C	PI
tesamorelin acetate	Egrifta	somatropin; GRF analog	SQ	2mg	X	PI
topiramate	Topamax	antiepileptic	tablets, sprinkle	25-400mg	D	PI
ulipristal acetate	Ella	contraceptive	tablets	30mg	X	PI
vemurafenib	Zelboraf	antineoplastic	tablets	960mg	D	PI
voriconazole	VFEND	antifungal	tabets, oral suspension, IV	4mg/kg IV, 200mg	D	PI
warfarin	Coumadin	anticoagulant	IV, tablets	2-10mg	X	PI

Drugs with Manufacturer's Safe Handling Guidelines that will be Added to the 2012 Hazardous Drug List

brentuximab vedotin	Adcetris	antineoplastic; monoclonal	IV	1.8mg/kg	D	PI
cabazitaxel	Jevtana Kit	antineoplastic; microtubule inhibitor	IV	25mg/m2	D	PI
dexrazoxane	Zinecard	chelator	IV	250-500mg/m2	D	PI
vandetanib	Caprelsa	antineoplastic; kinase inhibitor	tablets	300mg	D	PI

Drug Recommended to be Removed from the 2012 Hazardous Drug List

tetracycline		antibiotic	capsules	500mg	D	PI
--------------	--	------------	----------	-------	---	--------------------